

List of Study Group 2020-2021

2021

1. Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. *Int J Hematol.* 2021;113:73-80.
2. Lee HS, Kim K, Lee J-J, Yoon S-S, Bang S-M, Kim JS, et al., Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. *Int J Hematol.* 2021;113:81-91.
3. Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. *Int J Hematol.* 2021;113:106-11.
4. Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, et al. Makoto Onizuka, Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. *Int J Hematol.* 2021;113:128-33.
5. Yabe M, Morio T, Tabuchi K, Tomizawa D, Hasegawa D, Ishida H, et al. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. *Int J Hematol.* 2021;113:134-44.
6. Iida S, Ishida T, Horimoto K, Kazama H, Kim H, Crawford B. Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) – a focus on healthcare resource utilization and cost. *Int J Hematol.* 2021;113:271-8.

7. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, et al. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. *Int J Hematol.* 2021;113:395-403.
8. Ieko M, Hotta T, Watanabe K, Adachi T, Takeuchi S, Naito S, et al. Comparative evaluation of reagents for measuring protein S activity: possibility of harmonization. *Int J Hematol.* 2021;113:530-6.
9. Soejima T, Shiohara M, Ishida Y, Inoue M, Hayakawa A, Sato A, et al. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study. *Int J Hematol.* 2021;113:566-75.
Correction to: Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study: <https://link.springer.com/article/10.1007/s12185-021-03090-1>
10. Morishige S, Miyamoto T, Eto T, Uchida N, Kamimura T, Miyazaki Y, et al. Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008. *Int J Hematol.* 2021;113:815-22.
11. Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, et al. Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. *Int J Hematol.* 2021;113: 840-50.
12. Ishida H, Yano M, Hasegawa D, Hori T, Hashii Y, Kato K, et al. Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study. *Int J Hematol.*

2021;113:893-902.

13. Hosen N, Yoshihara S, Takamatsu Hi, Ri M, Nagata Y, Kosugi H, et al. Expression of activated integrin $\beta 7$ in multiple myeloma patients. *Int J Hematol.* 2021;114:3-7.
14. Tanaka C, Tagami T, Kudo S, Takehara A, Fukuda R, Nakayama F, et al. Validation of sepsis-induced coagulopathy score in critically ill patients with septic shock: post hoc analysis of a nationwide multicenter observational study in Japan. *Int J Hematol.* 2021;114:164-71.
15. Konishi T, Sekiya N, Otsuka Y, Konuma R, Wada A, Adachi H, et al. Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. *Int J Hematol.* 2021;114:263-70.
16. Arakawa Y, Masutani S, Oshima K, Mitani Y, Mori M, Fukuoka K, et al. Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia. *Int J Hematol.* 2021;114:271-9.
17. Lee Y-P, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen T-Y, et al. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. *Int J Hematol.* 2021;114:355-62.
18. Okamoto A, Kanda Y, Kimura S, Oyake T, Tamura K & from the Japan Febrile Neutropenia Study Group. Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study. *Int J Hematol.* 2021;114:472-82.

19. Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, et al. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy. 10.1007/s12185-021-03198-4
20. Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. 10.1007/s12185-021-03216-5
21. Favorable prognosis of vaccine-associated immune thrombocytopenia in children is correlated with young age at vaccination: Retrospective survey of nationwide disease registration. In press.

*****2020*****

1. Terakura S, Onizuka M, Fukumoto M, et al. Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. *Int J Hematol.* 2020;111:84-92.
2. Yanada M, Takami A, Mizuno S, et al. Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. *Int J Hematol.* 2020;111:93-102.
3. Kudo K, Maeda M, Suzuki N, et al. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. *Int J Hematol.* 2020;111:137-48.
4. Masaki Y, Kawabata Hi, Takai K. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. *Int J Hematol.* 2020;111:155-58.
- 5.
6. Nakaya A, Kohara T, Shibayama H, et al. Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry. *Int J Hematol.* 2020;112:435-8.
7. Ishiyama K, Nakao S, Usuki Kensuke, et al. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. *Int J Hematol.* 2020;112:466-76.
8. Uchida N, Matsumoto K, Sakura T, et al. Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS

patients over 54 years old: combined results of three phase II studies. *Int J Hematol.* 2020;112:510-23.

9. Yokohama A, Okuyama Y, Ueda Y, et al. Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan. *Int J Hematol.* 2020;112:535-43.
10. Hayase T, Saito S, Shioda Y, et al. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan. *Int J Hematol.* 2020;112:560-7.
11. Ieko M, Komiyama Y, Yamazaki S, Expert consensus regarding standardization of sample preparation for clotting time assays. *Int J Hematol.* 2020;112:614-20.
12. Ito A, Kim S-W, Matsuoka K, Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. *Int J Hematol.* 2020;112:674-89.
13. Kumamoto T, Goto H, Ogawa C, FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. *Int J Hematol.* 2020;112:720-4.
14. Matsuda S, Suzuki R, Takahashi T, et al. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. *Int J Hematol.* 2020;112:807-16.